MA29354B1 - Derives de cyclopentapyridine et tetrahydroquinoleine. - Google Patents
Derives de cyclopentapyridine et tetrahydroquinoleine.Info
- Publication number
- MA29354B1 MA29354B1 MA30262A MA30262A MA29354B1 MA 29354 B1 MA29354 B1 MA 29354B1 MA 30262 A MA30262 A MA 30262A MA 30262 A MA30262 A MA 30262A MA 29354 B1 MA29354 B1 MA 29354B1
- Authority
- MA
- Morocco
- Prior art keywords
- cyclopentapyridine
- tetrahydroquinoline
- derivatives
- tetrahydroquinoline derivatives
- cyclopenta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Dérivés de cyclopentapyridine et tétrahydroquinoléine Des dérivés de 6,7-dihydro-5H-cyclopenta[b]pyridine et de 5,6,7,8-tétrahydroquinoléine de formule (I), ainsi que leurs sels, leurs hydrates et produits de solvatation, qui agissent comme des ligands du récepteur 5-HT2 et leurs utilisations dans le traitement de maladies en rapport avec l'activation des récepteurs 5-HT2C sont décrits dans le présent mémoire.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66718405P | 2005-03-31 | 2005-03-31 | |
US76215906P | 2006-01-26 | 2006-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29354B1 true MA29354B1 (fr) | 2008-03-03 |
Family
ID=36218589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30262A MA29354B1 (fr) | 2005-03-31 | 2007-09-28 | Derives de cyclopentapyridine et tetrahydroquinoleine. |
Country Status (24)
Country | Link |
---|---|
US (1) | US7507732B2 (fr) |
EP (1) | EP1869000A1 (fr) |
JP (1) | JP4318744B2 (fr) |
KR (1) | KR100894006B1 (fr) |
AP (1) | AP2007004144A0 (fr) |
AR (1) | AR054021A1 (fr) |
AU (1) | AU2006228378A1 (fr) |
BR (1) | BRPI0609268A2 (fr) |
CA (1) | CA2602348C (fr) |
CR (1) | CR9386A (fr) |
DO (1) | DOP2006000076A (fr) |
EA (1) | EA200701853A1 (fr) |
GT (1) | GT200600128A (fr) |
IL (1) | IL185492A0 (fr) |
MA (1) | MA29354B1 (fr) |
MX (1) | MX2007012082A (fr) |
NL (1) | NL1031473C2 (fr) |
NO (1) | NO20074368L (fr) |
NZ (1) | NZ560917A (fr) |
PE (1) | PE20061333A1 (fr) |
TN (1) | TNSN07367A1 (fr) |
TW (1) | TW200722423A (fr) |
UY (1) | UY29446A1 (fr) |
WO (1) | WO2006103511A1 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2551552A1 (fr) | 2003-12-23 | 2005-07-14 | Myogen, Inc. | Modulateurs de recepteurs 5-ht2, leurs compositions pharmaceutiques et leur utilisation pour le traitement de maladies cardio-vasculaires et musculaires |
WO2006064780A1 (fr) * | 2004-12-14 | 2006-06-22 | Shionogi & Co., Ltd. | Agent therapeutique pour la constipation |
EP2018863B9 (fr) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique fusionné et utilisation |
ATE496894T1 (de) * | 2006-07-14 | 2011-02-15 | Pfizer Prod Inc | Tartratsalz von (7s)-7-ä(5-fluor-2- |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
EP2099763B1 (fr) * | 2006-12-07 | 2010-08-11 | F. Hoffmann-La Roche AG | 2-aminoquinolines comme antagonistes des récepteurs 5ht(5a) |
JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
KR20100109978A (ko) | 2008-03-07 | 2010-10-11 | 에프. 호프만-라 로슈 아게 | 2-아미노퀴놀린 유도체 |
EP2116618A1 (fr) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnostic et traitement de la maladie de Kawasaki |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α7活化劑之用途 |
JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
US8674218B2 (en) | 2010-12-15 | 2014-03-18 | General Electric Company | Restraint system for an energy storage device |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
EP2683704B1 (fr) | 2011-03-08 | 2014-12-17 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2015066344A1 (fr) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation |
US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
CN110236526B (zh) * | 2019-06-28 | 2022-01-28 | 李秋 | 基于咀嚼吞咽动作及心电活动的摄食行为分析和检测方法 |
WO2024026423A1 (fr) * | 2022-07-27 | 2024-02-01 | Black Diamond Therapeutics, Inc. | Dérivés de quinoléine substitués utiles comme inhibiteurs de pi3k |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01211581A (ja) | 1988-02-18 | 1989-08-24 | Meiji Seika Kaisha Ltd | シクロペンテノピリジン誘導体および抗潰瘍剤 |
US4985352A (en) * | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
EP0361489A3 (fr) | 1988-09-30 | 1991-06-12 | Chugai Seiyaku Kabushiki Kaisha | Composés de 3,4-diaminoquinoline et de pyridine |
ATE107922T1 (de) | 1989-03-03 | 1994-07-15 | Dainippon Pharmaceutical Co | 2-(1-piperazinyl)-4-phenylcycloalkanpyridin- derivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
JP2660086B2 (ja) | 1990-07-03 | 1997-10-08 | 明治製菓株式会社 | 脳及び心機能障害改善剤 |
JPH04103572A (ja) | 1990-08-20 | 1992-04-06 | Dainippon Pharmaceut Co Ltd | 4―フェニル―2―(1―ピペラジニル)ピリジン誘導体 |
EP0572863A1 (fr) | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | Pyrazinoindoles à activité sur le SNC |
DE4326151A1 (de) * | 1993-08-04 | 1995-02-09 | Hoechst Ag | Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen |
TW334423B (en) | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
TW270114B (fr) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
US5698766A (en) * | 1995-04-05 | 1997-12-16 | The Regents Of The University Of California | Transgenic animal model for testing drugs for treating eating disorders and epilepsy |
TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
AU5343298A (en) | 1997-01-13 | 1998-08-03 | Yamanouchi Pharmaceutical Co., Ltd. | 5-ht2c receptor agonists and aminoalkylindazole derivatives |
ES2208812T3 (es) | 1997-02-25 | 2004-06-16 | Akzo Nobel N.V. | Derivados de azetidina y de pirrolidina. |
US6322738B1 (en) | 1997-07-24 | 2001-11-27 | Husky Injection Molding Systems Ltd. | Method of injection over-molding articles |
US6040448A (en) * | 1997-10-24 | 2000-03-21 | Neurogen Corporation | Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands |
WO1999021850A1 (fr) | 1997-10-24 | 1999-05-06 | Neurogen Corporation | Piperazines de 1-(2-naphtyle) et de 1-(2-azanaphtyle)-4-(1-phenylmethyle)en tant que ligands pour le sous-type du recepteur de la dopamine d¿4? |
AU4037699A (en) | 1998-05-08 | 1999-11-29 | Akzo Nobel N.V. | Novel aryl-hydro naphthalenal kanamines |
EP1109544A4 (fr) | 1998-09-01 | 2004-10-27 | Bristol Myers Squibb Co | Inhibiteurs de canaux potassium et leur methode d'utilisation |
GB9819033D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
GB9819019D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
GB9819035D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
GB9819020D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds III |
JP2000191533A (ja) | 1998-10-19 | 2000-07-11 | Eisai Co Ltd | 鎮痛剤 |
AU1738900A (en) | 1998-11-19 | 2000-06-05 | Nortran Pharmaceuticals Inc. | Serotonin ligands as pro-erectile compounds |
CA2361516A1 (fr) | 1999-01-27 | 2000-08-03 | Jeffrey Thomas Mullaney | Aminoalkylbenzofurannes faisant office d'agonistes de la serotonine (5-ht(2c)) |
ATE313535T1 (de) | 1999-05-21 | 2006-01-15 | Pyrazinyl-piperazin-verbindungen, ihre anwendung und herstellung | |
WO2002010231A2 (fr) * | 2000-07-28 | 2002-02-07 | Goodrich Corporation | Compositions polymeriques utiles pour former des guides d'ondes optiques et guides d'ondes optiques formes a partir de ces compositions et procedes de fabrication des memes |
AU2426602A (en) | 2000-11-20 | 2002-05-27 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
SE0004245D0 (sv) * | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
TWI245761B (en) | 2001-03-01 | 2005-12-21 | Telik Inc | Antagonists of MCP-1 function and methods of use thereof |
ES2278016T3 (es) | 2001-04-09 | 2007-08-01 | Novartis Vaccines And Diagnostics, Inc. | Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r). |
US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
AU2004229404B2 (en) * | 2003-04-11 | 2008-01-10 | Taigen Biotechnology | Aminoquinoline compounds |
US7101881B2 (en) | 2003-06-11 | 2006-09-05 | Pfizer Inc | Tetrahydroquinolines |
WO2006015263A2 (fr) | 2004-07-29 | 2006-02-09 | Threshold Pharmaceuticals, Inc. | Analogues de lonidamine |
-
2006
- 2006-03-21 JP JP2008503608A patent/JP4318744B2/ja not_active Expired - Fee Related
- 2006-03-21 EA EA200701853A patent/EA200701853A1/ru unknown
- 2006-03-21 CA CA2602348A patent/CA2602348C/fr not_active Expired - Fee Related
- 2006-03-21 AU AU2006228378A patent/AU2006228378A1/en not_active Abandoned
- 2006-03-21 BR BRPI0609268-3A patent/BRPI0609268A2/pt not_active IP Right Cessation
- 2006-03-21 NZ NZ560917A patent/NZ560917A/en not_active IP Right Cessation
- 2006-03-21 MX MX2007012082A patent/MX2007012082A/es active IP Right Grant
- 2006-03-21 WO PCT/IB2006/000655 patent/WO2006103511A1/fr not_active Application Discontinuation
- 2006-03-21 KR KR1020077022374A patent/KR100894006B1/ko not_active IP Right Cessation
- 2006-03-21 AP AP2007004144A patent/AP2007004144A0/xx unknown
- 2006-03-21 EP EP06710585A patent/EP1869000A1/fr not_active Withdrawn
- 2006-03-28 PE PE2006000343A patent/PE20061333A1/es not_active Application Discontinuation
- 2006-03-29 AR ARP060101218A patent/AR054021A1/es unknown
- 2006-03-29 GT GT200600128A patent/GT200600128A/es unknown
- 2006-03-30 DO DO2006000076A patent/DOP2006000076A/es unknown
- 2006-03-30 TW TW095111125A patent/TW200722423A/zh unknown
- 2006-03-30 UY UY29446A patent/UY29446A1/es not_active Application Discontinuation
- 2006-03-30 NL NL1031473A patent/NL1031473C2/nl not_active IP Right Cessation
- 2006-03-31 US US11/395,327 patent/US7507732B2/en not_active Expired - Fee Related
-
2007
- 2007-08-23 IL IL185492A patent/IL185492A0/en unknown
- 2007-08-27 NO NO20074368A patent/NO20074368L/no not_active Application Discontinuation
- 2007-09-19 CR CR9386A patent/CR9386A/es not_active Application Discontinuation
- 2007-09-28 TN TNP2007000367A patent/TNSN07367A1/fr unknown
- 2007-09-28 MA MA30262A patent/MA29354B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US20060247254A1 (en) | 2006-11-02 |
US7507732B2 (en) | 2009-03-24 |
CA2602348C (fr) | 2011-03-01 |
PE20061333A1 (es) | 2007-01-13 |
KR20070107183A (ko) | 2007-11-06 |
JP4318744B2 (ja) | 2009-08-26 |
NL1031473C2 (nl) | 2007-03-19 |
JP2008534568A (ja) | 2008-08-28 |
EP1869000A1 (fr) | 2007-12-26 |
WO2006103511A1 (fr) | 2006-10-05 |
TW200722423A (en) | 2007-06-16 |
BRPI0609268A2 (pt) | 2010-03-09 |
UY29446A1 (es) | 2006-10-31 |
AU2006228378A1 (en) | 2006-10-05 |
EA200701853A1 (ru) | 2008-08-29 |
TNSN07367A1 (fr) | 2008-12-31 |
MX2007012082A (es) | 2007-11-20 |
NZ560917A (en) | 2011-01-28 |
NO20074368L (no) | 2007-09-21 |
IL185492A0 (en) | 2008-01-06 |
NL1031473A1 (nl) | 2006-10-03 |
KR100894006B1 (ko) | 2009-04-17 |
CR9386A (es) | 2007-10-02 |
DOP2006000076A (es) | 2006-11-30 |
CA2602348A1 (fr) | 2006-10-05 |
AR054021A1 (es) | 2007-05-30 |
GT200600128A (es) | 2007-03-29 |
AP2007004144A0 (en) | 2007-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29354B1 (fr) | Derives de cyclopentapyridine et tetrahydroquinoleine. | |
TNSN03143A1 (fr) | Ligands de recepteurs de 5-ht et leurs utilisations . | |
TNSN05121A1 (fr) | Purines et leurs utilisations comme ligands des recepteurs de cannabinoides | |
MA31906B1 (fr) | Inhibiteurs de la replication du virus de limmunodeficience humaine | |
TNSN05190A1 (fr) | DERIVES DE PYRAZOLO [1,5-a][1,3,5] TRIAZINE SERVANT DE LIGANDS DES RECEPTEURS DE CANNABINOIDES | |
MA33155B1 (fr) | Composes organiques et leurs utilisations | |
MA32134B1 (fr) | Composés hétérocycliques | |
MXPA05013282A (es) | Derivados de pirimidina como ligandos del receptor de cannabinoides. | |
TW200745079A (en) | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor | |
MA27767A1 (fr) | Ligands des recepteurs de cannabinoides et leurs utilisations | |
TN2012000073A1 (fr) | Derives des l-(piperidine-4-yl) pyrazole servant de modulateurs de gpr119 | |
MA33134B1 (fr) | Derives d'indole en tant qu'antagonistes du recepteur crth2 | |
MXPA05011922A (es) | Ligandos del receptor de cannabinoides y sus usos. | |
MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
MA32306B1 (fr) | Derives de quinoleines et de quinoxalines en tant qu'inhibiteurs de proteine tyrosine kinases | |
MXPA05010164A (es) | Ligandos de receptores de canabinoides y sus usos. | |
NZ547615A (en) | Quinoline derivatives and use thereof as mycobacterial inhibitors | |
EA200970519A1 (ru) | Полиморфы сукцината 2-[6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2h-пиримидин-1-илметил]-4-фторбензонитрил и способы их применения | |
MXPA05011362A (es) | Ligandos de receptor cannabinoide y usos de los mismos. | |
WO2007020502A3 (fr) | Ligands des recepteurs de cannabinoide et utilisations de ceux-ci | |
ECSP056111A (es) | Derivados de 2-acilamino-4-feniltiazol, su preparación y aplicación en terapeutica | |
DE60139021D1 (de) | Piperazinylpyrazinverbindungen als antagonisten des serotonin-5-ht2-rezeptors | |
DE502005006149D1 (de) | Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer | |
MA34650B1 (fr) | Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda |